INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2017

Oral nicotinamide riboside was well tolerated and doubled steady-state whole blood NAD+ levels in healthy volunteers.

In an open-label pharmacokinetic study, 8 healthy volunteers took 250 mg oral nicotinamide riboside (NR) on Days 1 and 2, which was uptitrated to 1000 mg twice daily on Days 7 and 8, followed by a 24-hour pharmacokinetic evaluation on Day 9. Oral NR was well tolerated with no adverse events. Significant increases from baseline to steady-state mean concentrations were observed for both NR (p = 0.03) and NAD+ (p = 0.001), with NAD+ increasing by 100%. Absolute changes from baseline to Day 9 in NR and NAD+ levels were highly correlated (R2 = 0.72, p = 0.008).

Study type
Open-label, non-randomized pharmacokinetic study
Who was studied
8 healthy volunteers
What was measured
Human pharmacokinetics of oral NR and whole blood NAD+ levels

THE PAPER

An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers.

Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. PLoS One, 2017.

PubMed 29211728 ↗DOI 10.1172/jci64264 ↗

Nutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.